vs

Side-by-side financial comparison of indie Semiconductor, Inc. (INDI) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $58.0M, roughly 1.2× indie Semiconductor, Inc.). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -53.8%, a 437.9% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs -0.0%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 5.3%).

indie Semiconductor is a fabless semiconductor manufacturer focused on designing high-performance mixed-signal and embedded system-on-chip solutions for the automotive industry. Its products support advanced driver assistance systems, in-vehicle infotainment, connected car, and electric vehicle applications, serving global auto OEMs and tier 1 suppliers across major global markets.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

INDI vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.2× larger
RIGL
$69.8M
$58.0M
INDI
Growing faster (revenue YoY)
RIGL
RIGL
+21.2% gap
RIGL
21.2%
-0.0%
INDI
Higher net margin
RIGL
RIGL
437.9% more per $
RIGL
384.0%
-53.8%
INDI
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
5.3%
INDI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INDI
INDI
RIGL
RIGL
Revenue
$58.0M
$69.8M
Net Profit
$-31.2M
$268.1M
Gross Margin
37.3%
91.5%
Operating Margin
-58.5%
33.2%
Net Margin
-53.8%
384.0%
Revenue YoY
-0.0%
21.2%
Net Profit YoY
9.1%
1769.2%
EPS (diluted)
$-0.16
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INDI
INDI
RIGL
RIGL
Q4 25
$58.0M
$69.8M
Q3 25
$53.7M
$69.5M
Q2 25
$51.6M
$101.7M
Q1 25
$54.1M
$53.3M
Q4 24
$58.0M
$57.6M
Q3 24
$54.0M
$55.3M
Q2 24
$52.4M
$36.8M
Q1 24
$52.4M
$29.5M
Net Profit
INDI
INDI
RIGL
RIGL
Q4 25
$-31.2M
$268.1M
Q3 25
$-38.3M
$27.9M
Q2 25
$-39.0M
$59.6M
Q1 25
$-34.5M
$11.4M
Q4 24
$-34.4M
$14.3M
Q3 24
$-49.7M
$12.4M
Q2 24
$-19.2M
$-1.0M
Q1 24
$-31.2M
$-8.2M
Gross Margin
INDI
INDI
RIGL
RIGL
Q4 25
37.3%
91.5%
Q3 25
40.1%
93.2%
Q2 25
40.6%
95.6%
Q1 25
41.7%
91.7%
Q4 24
42.6%
89.9%
Q3 24
39.3%
85.5%
Q2 24
42.2%
92.4%
Q1 24
42.5%
93.1%
Operating Margin
INDI
INDI
RIGL
RIGL
Q4 25
-58.5%
33.2%
Q3 25
-71.4%
40.9%
Q2 25
-83.3%
60.1%
Q1 25
-72.0%
23.9%
Q4 24
-58.4%
28.9%
Q3 24
-92.5%
25.4%
Q2 24
-70.0%
1.2%
Q1 24
-94.8%
-23.6%
Net Margin
INDI
INDI
RIGL
RIGL
Q4 25
-53.8%
384.0%
Q3 25
-71.3%
40.2%
Q2 25
-75.6%
58.6%
Q1 25
-63.9%
21.5%
Q4 24
-59.2%
24.9%
Q3 24
-92.1%
22.5%
Q2 24
-36.6%
-2.8%
Q1 24
-59.6%
-27.9%
EPS (diluted)
INDI
INDI
RIGL
RIGL
Q4 25
$-0.16
$14.11
Q3 25
$-0.19
$1.46
Q2 25
$-0.20
$3.28
Q1 25
$-0.18
$0.63
Q4 24
$-0.18
$0.82
Q3 24
$-0.28
$0.70
Q2 24
$-0.11
$-0.06
Q1 24
$-0.19
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INDI
INDI
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$145.5M
$155.0M
Total DebtLower is stronger
$353.4M
$52.5M
Stockholders' EquityBook value
$358.0M
$391.5M
Total Assets
$840.8M
$513.6M
Debt / EquityLower = less leverage
0.99×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INDI
INDI
RIGL
RIGL
Q4 25
$145.5M
$155.0M
Q3 25
$160.9M
$137.1M
Q2 25
$192.6M
$108.4M
Q1 25
$236.6M
$77.1M
Q4 24
$274.2M
$77.3M
Q3 24
$96.9M
$61.1M
Q2 24
$112.3M
$49.1M
Q1 24
$138.2M
$49.5M
Total Debt
INDI
INDI
RIGL
RIGL
Q4 25
$353.4M
$52.5M
Q3 25
$353.5M
$60.0M
Q2 25
$352.5M
$60.0M
Q1 25
$379.0M
$60.0M
Q4 24
$381.3M
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
INDI
INDI
RIGL
RIGL
Q4 25
$358.0M
$391.5M
Q3 25
$369.2M
$117.6M
Q2 25
$390.4M
$81.9M
Q1 25
$405.6M
$18.6M
Q4 24
$417.9M
$3.3M
Q3 24
$458.6M
$-14.6M
Q2 24
$470.7M
$-29.9M
Q1 24
$432.9M
$-31.7M
Total Assets
INDI
INDI
RIGL
RIGL
Q4 25
$840.8M
$513.6M
Q3 25
$855.1M
$242.5M
Q2 25
$867.6M
$206.7M
Q1 25
$909.0M
$176.0M
Q4 24
$941.4M
$164.0M
Q3 24
$797.5M
$139.4M
Q2 24
$797.3M
$128.4M
Q1 24
$803.6M
$126.5M
Debt / Equity
INDI
INDI
RIGL
RIGL
Q4 25
0.99×
0.13×
Q3 25
0.96×
0.51×
Q2 25
0.90×
0.73×
Q1 25
0.93×
3.23×
Q4 24
0.91×
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INDI
INDI
RIGL
RIGL
Operating Cash FlowLast quarter
$-14.4M
$22.0M
Free Cash FlowOCF − Capex
$-16.1M
FCF MarginFCF / Revenue
-27.8%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$-71.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INDI
INDI
RIGL
RIGL
Q4 25
$-14.4M
$22.0M
Q3 25
$-6.2M
$24.0M
Q2 25
$-7.6M
$30.5M
Q1 25
$-29.0M
$-893.0K
Q4 24
$-6.7M
$14.5M
Q3 24
$-22.8M
$21.7M
Q2 24
$-19.7M
$302.0K
Q1 24
$-9.3M
$-5.0M
Free Cash Flow
INDI
INDI
RIGL
RIGL
Q4 25
$-16.1M
Q3 25
$-10.3M
Q2 25
$-13.6M
Q1 25
$-31.4M
Q4 24
$-8.6M
Q3 24
$-29.3M
Q2 24
$-23.4M
Q1 24
$-11.7M
FCF Margin
INDI
INDI
RIGL
RIGL
Q4 25
-27.8%
Q3 25
-19.2%
Q2 25
-26.4%
Q1 25
-58.0%
Q4 24
-14.8%
Q3 24
-54.3%
Q2 24
-44.7%
Q1 24
-22.3%
Capex Intensity
INDI
INDI
RIGL
RIGL
Q4 25
3.0%
Q3 25
7.8%
Q2 25
11.6%
Q1 25
4.4%
Q4 24
3.2%
Q3 24
12.1%
Q2 24
7.0%
Q1 24
4.4%
Cash Conversion
INDI
INDI
RIGL
RIGL
Q4 25
0.08×
Q3 25
0.86×
Q2 25
0.51×
Q1 25
-0.08×
Q4 24
1.01×
Q3 24
1.75×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INDI
INDI

Products$55.7M96%
Services$2.3M4%

RIGL
RIGL

Segment breakdown not available.

Related Comparisons